A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I

Abstract excerpt

Our previous study delivered zinc finger nucleases to treat mice with mucopolysaccharidosis type I (MPS I), resulting in a phase I/II clinical trial (ClinicalTrials.gov: NCT02702115). However, in the clinical trial, the efficacy needs to be improved due to the low transgene expression level. To this end, we designed a proprietary system (PS) gene editing approach with CRISPR to insert a promoterless...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Autism Spectrum Disorder Research
• Share to CRISPR and Genetic Engineering
• Share to Lysosomal Storage Disorders Research